• Hydrix (ASX:HYD) had some more good news for its AngelMed Guardian heart monitoring system.
  • The technology was successfully implanted in a patient in the US for the first time.
  • It follows four successful implants for patients in Singapore last month, as the company moves towards commercialisation.

Diversified engineering firm Hydrix (ASX:HYD) continues to find momentum with AngelMed Guardian, its implantable heart-monitoring technology.

The company today announced the first successful implant of the device in a US patient.

Shares in HYD jumped back to around 40c — a morning gain of more than 40 per cent.

A previous announcement in early August, where Hydrix said the device had been successfully implanted in four patients in Singapore, gave rise to an intraday stock surge of more than 250 per cent.


The first US implant was carried out as part of a continued access study with the US Food & Drug Administration.

As part of the study, HYD received approval to re-implant the latest version of its device on 260 clinical trial patients.

The implanting surgeon, Kelly Tucker, said the AngelMed device is a “game-changing” technology for people with heart problems.

“This is the first ever surveillance tool for patients with a prior coronary event and has the potential to save countless lives and bring peace of mind to thousands of families,” Tucker said.

The AngelMed device is designed to detect abnormal patterns in the electronic signal of each patients heart.

It then activates a warning system, effectively acting as a preventative measure for symptoms of Acute Coronary Syndrome such as silent heart attacks.

Paul Kelly, Hydrix Medical general manager Paul Kelly said the successful implant is a “significant step forward in the progress of the AngelMed Guardian’s commercialisation”.

As part of a deal signed in July 2019, Hydrix acquired the distribution rights for AngelMed throughout the Asia-Pacific region.